Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-DIMERPA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARO-DIMERPA | EXPERIMENTAL | ARO-DIMERPA in single or multiple ascending doses |
| Placebo | PLACEBO_COMPARATOR | Placebo (normal saline, 0.9%) in single or multiple matching doses |
| Name | Type | Description |
|---|---|---|
| ARO-DIMERPA | DRUG | Subcutaneous (SC) injection |
| Placebo | DRUG | Calculated volume to match active treatment by SC injection |
Inclusion Criteria: * Willing to follow diet counseling as per Investigator judgment based on local standard of care * Specific fasting TG, LDL-C, and non-high density lipoprotein cholesterol levels at Screening * Participants of childbearing potential must agree to use highly effective contracepti...
ARO-DIMERPA is an investigational small molecule being developed by Arrowhead Pharmaceuticals, Inc. for the treatment of mixed hyperlipidemia, a condition marked by elevated lipids in the blood. It is currently in Phase 1 clinical development and has not been approved by the FDA.
ARO-DIMERPA targets PCSK9 and APOC3, two proteins involved in lipid metabolism. By acting on both targets, the drug is designed to lower circulating lipids in patients with mixed hyperlipidemia. It is a small molecule modality in development by Arrowhead Pharmaceuticals.
ARO-DIMERPA is being developed by Arrowhead Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ARWR. Arrowhead is the sponsor of the clinical program evaluating the drug in adults with mixed hyperlipidemia.
ARO-DIMERPA is in Phase 1 clinical development. It is investigational and has not received FDA approval. The program currently has one active, recruiting trial, with no completed trials to date.
ARO-DIMERPA is being studied in one Phase 1 trial, NCT07223658, titled Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia. The trial is recruiting, is randomized, double-blind, and placebo-controlled, and plans to enroll 78 participants across Australia, Canada, Georgia, Moldova, and New Zealand.
The Phase 1 trial NCT07223658 enrolls adults 18 years of age and older of any sex with mixed hyperlipidemia. It does not accept healthy volunteers. The study is randomized, double-blind, and placebo-controlled, with a planned enrollment of 78 participants.